Friday, February 25, 2011
Lu AA24493 - Expected report data of clinical phase II
Lu AA24493 (novel carbamoylated form of human erythropoietin (EPO)) is in clinical phase II in the treatment of Friedreich's ataxia and in clinical phase I in the treatment of acute ischaemic stroke. Ongoing studies in both programmes are expected to report data in the first half of 2011.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment